Unmask Cancer,
Elicit Immune Response

Read more

Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases

A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key N-glycosylation mechanism responsible for suppressing the immune response.

Our first generation of N-glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.



Phost’in Therapeutics announces €2.5m funding from Bpifrance to support regulatory and early clinical development of its First-In-Class N-Glycosylation Inhibitor

Montpellier, France – Sept 2020, 11th
Read more

Phost'in Therapeutics strengthens management with appointment of veteran lifescience executives Dr. Alain Herrera and Pr. Bernard Pau

Montpellier, France – June 2020, 17th
Read more

€10M Series A Boosts Cancer Immunotherapy Hitting Tumor Sugar Coating

LABIOTECH.eu – April 2020, 22nd
Read more

Phost’in Therapeutics raises €10.3m to develop First-in-Class N-glycosylation Inhibitors for Cancer Treatment

Montpellier, France – April 2020, 20th
Read more